Efficacy and safety of continuous 4-year telbivudine treatment in patients with chronic hepatitis B

by Wang Y., Thongsawat S., Gane E.J., Liaw Y.-F., Jia J., Hou J., Chan H.L.Y., Papatheodoridis G., Wan M., Niu J., Bao W., Trylesinski A., Naoumov N.V.
Published 2014

Efficacy and safety of prolonged 3-year telbivudine treatment in patients with chronic hepatitis B

by Gane E., Wang Y., Liaw Y., Hou J., Thongsawat S., Wan M., Moon Y., Jia J., Chao Y., Niu J., Leung N., Samuel D., Hsu C., Bao W., Lopez P., Avila C.
Published 2017

Baseline characteristics and early on-treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B

by Zeuzem, S., Gane, E., Liaw, Y.-F., Lim, S.G., DiBisceglie, A., Buti, M., Chutaputti, A., Rasenack, J., Hou, J., O'Brien, C., Nguyen, T.T., Jia, J., Poynard, T., Belanger, B., Bao, W., Naoumov, N.V.
Published 2016

Randomized, controlled pharmacokinetic and pharmacodynamic evaluation of albinterferon in patients with chronic hepatitis B infection

by Colvin,R.A., Tanwandee,T., Piratvisuth,T., Thongsawat,S., Hui,A., Zhang,H., Ren,H., Chen,P., Chuang,W., Sobhonslidsuk,A., Li,R., Qi,Y., Præstgaard,J.T., Han,Y., Xu,J., Stein,D.S., Chien,R., Flisiak,R., Jabłkowski,M.S., Liaw,Y., Sung,J.J.Y.
Published 2015

Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma

by Omata, M., Tateishi, R., Yoshida, H., Shiina, S., Lesmana, L.A., Budihusodo, U., Lesmana, C.R., Chen, P.-J., Lin, S.-M., Liaw, Y.F., Kudo, M., Lee, J.M., Choi, B.I., Poon, R.T.P., Cheng, A.L., Jia, J.-D., Obi, S., Han, K.H., Jafri, W., Chow, P., Lim, S.G., Chawla, Y.K., Gani, R.A., Putranto, T.A., Sarin, S.K.
Published 2011